• 重症溃疡性结肠炎患者血清闭锁小带蛋白-1、GATA结合蛋白-3表达与预后有关
  • 阎春英.重症溃疡性结肠炎患者血清闭锁小带蛋白-1、GATA结合蛋白-3表达与预后有关[J].内科急危重症杂志,2023,29(4):290-292
    扫码阅读全文 本文二维码信息
    DOI:10.11768/nkjwzzzz20230407
    中文关键词:  闭锁小带蛋白-1  GATA结合蛋白-3  重症溃疡性结肠炎  预后
    英文关键词:
    基金项目:陕西省自然科学基础研究计划项目(No:2020JM-654)
    作者单位E-mail
    阎春英 陕西省人民医院 271101761@qq.com 
    摘要点击次数: 836
    全文下载次数: 971
    中文摘要:
          摘要 目的:检测重症溃疡性结肠炎(UC)患者血清中闭锁小带蛋白-1(ZO-1)、GATA结合蛋白-3(GATA-3)水平,探讨其与重症UC患者预后相关性。方法:收集重症UC患者97例为重症组,并根据患者预后情况将其分为预后良好组68例和预后不良组29例;另选取轻症UC患者50例为轻症组。采用酶联免疫吸附法(ELISA)检测各组患者血清ZO- 1、GATA-3水平,Pearson法分析ZO-1、GATA-3水平与Mayo评分的相关性,受试者工作特征(ROC)曲线分析血清ZO-1、GATA-3对重症UC患者预后不良的预测价值。结果:与轻症组比较,重症组患者血清ZO-1水平显著降低,血清GATA-3水平、Mayo评分显著升高(P均<0.05);相关性分析显示,重症UC患者血清ZO-1水平与Mayo评分呈负相关(r=-0.650,P<0.05),GATA-3水平与Mayo评分呈正相关(r=0.474,P<0.05);与预后良好组比较,预后不良组患者血清ZO-1水平显著降低,血清GATA-3水平、Mayo评分显著升高(P均<0.05);血清ZO-1、GATA-3及Mayo评分联合预测重症UC患者预后不良的曲线下面积为0.966,灵敏度为93.75%,特异性为92.31%。结论:重症UC患者血清ZO-1水平降低、GATA-3水平升高,且与患者疾病严重程度和预后有关,可能作为预测重症UC患者预后不良的潜在标志物。
    英文摘要:
          Abstract Objective: To detect the expression of zonula occluden-1 (ZO-1) and GATA-binding protein-3 (GATA-3) in the serum of patients with severe ulcerative colitis (UC), and to explore their correlation with the prognosis of patients with severe UC. Methods: A total of 97 patients with severe UC who were treated in our hospital from November 2019 to February 2021 were collected as the observation objects (critical group), and they were divided into 68 cases of a good prognosis group and 29 cases of a poor prognosis group according to the prognosis of the patients. A total of 50 patients with mild UC were selected as controls (mild group). Enzyme-linked immunosorbent assay (ELISA) was used to detect the expression levels of ZO-1 and GATA-3 in the serum. Pearson method was used to analyze the correlation between ZO-1, GATA-3 levels and Mayo score. The ROC curve was used to analyze the predictive value of serum ZO-1 and GATA-3 in poor prognosis of patients with severe UC. Results: Compared with the mild group, the serum ZO-1 level in the severe group was significantly reduced, and the serum GATA-3 and Mayo score were significantly increased (P<0.05). The correlation analysis showed that serum ZO-1 expression level in severe UC patients was negatively correlated with Mayo score (r=-0.650, P<0.05), and GATA-3 expression level was positively correlated with Mayo score (r=0.474, P<0.05). As compared with the good prognosis group, the serum ZO-1 level in the poor prognosis group was significantly reduced, and the serum GATA-3 level and Mayo score were significantly increased (P<0.05). The area under the curve for the combined detection of serum ZO-1, GATA-3 and Mayo scores to predict poor prognosis of patients with severe UC was 0.966, sensitivity was 93.75%, and specificity was 92.31%. Conclusion: The serum ZO-1 level in patients with severe UC decreases and the GATA-3 level increases. They are related to the disease severity and prognosis, and may be used as potential markers for predicting the poor prognosis of patients with severe UC.